|
Product
|
FGF-23, Human
|
|
Cat#
|
101-19-17A
|
|
Sequence
|
YPNASPLLGS SWGGLIHLYT ATARNSYHLQ IHKNGHVDGA
PHQTIYSALM IRSEDAGFVV ITGVMSRRYL CMDFRGNIFG SHYFDPENCR
FQHQTLENGY DVYHSPQYHF LVSLGRAKRA FLPGMNPPPY SQFLSRRNEI
PLIHFNTPIP RRHTRSAEDD SERDPLNVLK PRARMTPAPA SCSQELPSAE
DNSPMASDPL GVVRGGRVNT HAGGTGPEGC RPFAKFI
|
|
Unit/Weight
|
20 μg
|
|
Unit Price
|
$152.00
|
|
Description
|
Fibroblast growth factor-23 (FGF-23) belongs to the large FGF family which has at least 23 members. All FGF family members are heparin binding growth factors with a core 120 amino acid (a.a.) FGF domain that allows for a common tertiary structure. FGFs are expressed during embryonic development and in restricted adult tissues. Four distinct but related classes of FGF receptors, FGF R1, 2, 3, and 4, exist. FGF-23 is produced by osteocytes and osteoblasts in response to high circulating phosphate levels, elevated parathyroid hormone, and circulatory volume loading. It functions as an endocrine phosphatonin by suppressing circulating phosphate levels. FGF-23 interaction with renal proximal tubular epithelium decreases the renal resorption of phosphate by down regulating phosphate transporters and by suppressing vitamin D production. It also decreases the intestinal absorption of phosphate.
|
|
Molecular Weight
|
Approximately 25.3 kDa, a single non-glycosylated polypeptide chain containing 227 amino acids.
|
|
Purity
|
> 95 % by SDS-PAGE and HPLC analyses.
|
|
Storage
|
This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
|
|